Voyager Therapeutics (VYGR) Current Leases (2019 - 2026)

Voyager Therapeutics has disclosed Current Leases across 8 years of filings, most recently posting $7.4 million for Q1 2026.

• Current Leases for Q1 2026 came in at $7.4 million, down 0.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.4 million (down 0.9% YoY), and the FY2025 annual result was $7.8 million, up 8.48% from the prior year.
• Current Leases came in at $7.4 million for Q1 2026 at Voyager Therapeutics, down from $7.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $7.8 million in Q3 2025 to a low of $2.5 million in Q2 2022.
• The 5-year median for Current Leases is $5.9 million (2024), against an average of $5.4 million.
• Across the five-year window, Current Leases plunged 49.17% in 2022 and soared 125.84% in 2024, its largest moves.
• Voyager Therapeutics' Current Leases stood at $2.8 million in 2022, then climbed by 12.99% to $3.2 million in 2023, then jumped by 125.84% to $7.2 million in 2024, then climbed by 8.48% to $7.8 million in 2025, then dropped by 6.08% to $7.4 million in 2026.
• The last three Current Leases figures came in at $7.4 million (Q1 2026), $7.8 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.